There have been recent commentaries on the prospects and potential for both what is called “precision oncology” and Vice President Joe Biden’s Cancer Moonshot program. Although I have discussed both in the past, the current news, writes Dr. Vinay Prasad in the journal Nature, is quite “sobering.” The news is sobering because the hype and expectations are way beyond the truth. When costs are high—and in the case of precision oncology, they are extremely high—research efforts must focus on areas of likely success, not on high expense with little likelihood of return. Since myeloma is one of many cancers (and not the most common), we are particularly sensitive about the need to fully justify the spending of every research dollar.

click HERE to read Dr. Durie’s blog:

Tagged with →